Chromatin Accessibility Landscapes of Skin Cells in Systemic Sclerosis Nominate Dendritic Cells in Disease Pathogenesis
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
A Collagen-Remodeling Gene Signature Regulated by TGF-B Signaling Is Associated with Metastasis and Poor Survival in Serous Ovarian Cancer
Published OnlineFirst November 11, 2013; DOI: 10.1158/1078-0432.CCR-13-1256 Clinical Cancer Imaging, Diagnosis, Prognosis Research A Collagen-Remodeling Gene Signature Regulated by TGF-b Signaling Is Associated with Metastasis and Poor Survival in Serous Ovarian Cancer Dong-Joo Cheon1, Yunguang Tong2, Myung-Shin Sim7, Judy Dering6, Dror Berel3, Xiaojiang Cui1, Jenny Lester1, Jessica A. Beach1,5, Mourad Tighiouart3, Ann E. Walts4, Beth Y. Karlan1,6, and Sandra Orsulic1,6 Abstract Purpose: To elucidate molecular pathways contributing to metastatic cancer progression and poor clinical outcome in serous ovarian cancer. Experimental Design: Poor survival signatures from three different serous ovarian cancer datasets were compared and a common set of genes was identified. The predictive value of this gene signature was validated in independent datasets. The expression of the signature genes was evaluated in primary, metastatic, and/or recurrent cancers using quantitative PCR and in situ hybridization. Alterations in gene expression by TGF-b1 and functional consequences of loss of COL11A1 were evaluated using pharmacologic and knockdown approaches, respectively. Results: We identified and validated a 10-gene signature (AEBP1, COL11A1, COL5A1, COL6A2, LOX, POSTN, SNAI2, THBS2, TIMP3, and VCAN) that is associated with poor overall survival (OS) in patients with high-grade serous ovarian cancer. The signature genes encode extracellular matrix proteins involved in collagen remodeling. Expression of the signature genes is regulated by TGF-b1 signaling and is enriched in metastases in comparison with primary ovarian tumors. We demonstrate that levels of COL11A1, one of the signature genes, continuously increase during ovarian cancer disease progression, with the highest expression in recurrent metastases. -
A Meta-Analysis of the Inhibin Network Reveals Prognostic Value in Multiple Solid Tumors
bioRxiv preprint doi: https://doi.org/10.1101/2020.06.25.171942; this version posted June 27, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. 1 A meta-analysis of the inhibin network reveals prognostic value in multiple solid tumors Eduardo Listik1†, Ben Horst1,2†, Alex Seok Choi1, Nam. Y. Lee3, Balázs Győrffy4 and Karthikeyan Mythreye1 Affiliations: 1Department of Pathology, University of Alabama at Birmingham, Birmingham AL, USA, 35294. 2Department of Chemistry and Biochemistry, University of South Carolina, Columbia SC, USA, 29208. 3 Division of Pharmacology, Chemistry and Biochemistry, College of Medicine, University of Arizona, Tucson, AZ, 85721, USA. 4 TTK Cancer Biomarker Research Group, Institute of Enzymology, and Semmelweis University Department of Bioinformatics and 2nd Department of Pediatrics, Budapest, Hungary. Corresponding author: Karthikeyan Mythreye, Ph.D. Division of Molecular and Cellular Pathology, Department of Pathology, The University of Alabama at Birmingham. WTI 320B, 1824 Sixth Avenue South, Birmingham, AL, USA, 35294. Phone : +1 205.934.2746 E-mail : [email protected] †The authors contributed equally to this work. bioRxiv preprint doi: https://doi.org/10.1101/2020.06.25.171942; this version posted June 27, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. -
FOP) Can Be Rescued by the Drug Candidate Saracatinib
Stem Cell Reviews and Reports https://doi.org/10.1007/s12015-020-10103-9 ActivinA Induced SMAD1/5 Signaling in an iPSC Derived EC Model of Fibrodysplasia Ossificans Progressiva (FOP) Can Be Rescued by the Drug Candidate Saracatinib Susanne Hildebrandt1,2,3 & Branka Kampfrath1 & Kristin Fischer3,4 & Laura Hildebrand2,3 & Julia Haupt1 & Harald Stachelscheid3,4 & Petra Knaus 1,2 Accepted: 1 December 2020 # The Author(s) 2021 Abstract Balanced signal transduction is crucial in tissue patterning, particularly in the vasculature. Heterotopic ossification (HO) is tightly linked to vascularization with increased vessel number in hereditary forms of HO, such as Fibrodysplasia ossificans progressiva (FOP). FOP is caused by mutations in the BMP type I receptor ACVR1 leading to aberrant SMAD1/5 signaling in response to ActivinA. Whether observed vascular phenotype in human FOP lesions is connected to aberrant ActivinA signaling is unknown. Blocking of ActivinA prevents HO in FOP mice indicating a central role of the ligand in FOP. Here, we established a new FOP endothelial cell model generated from induced pluripotent stem cells (iECs) to study ActivinA signaling. FOP iECs recapitulate pathogenic ActivinA/SMAD1/5 signaling. Whole transcriptome analysis identified ActivinA mediated activation of the BMP/ NOTCH pathway exclusively in FOP iECs, which was rescued to WT transcriptional levels by the drug candidate Saracatinib. We propose that ActivinA causes transcriptional pre-patterning of the FOP endothelium, which might contribute to differential vascularity in FOP lesions compared to non-hereditary HO. Keywords FOP . BMP-receptor . Activin . iPSCs . Human endothelial cells . HO . Saracatinib Introduction pathological conditions such as cancer and chronic inflamma- tion [2]. -
Untwining Anti-Tumor and Immunosuppressive Effects of JAK Inhibitors—A Strategy for Hematological Malignancies?
cancers Review Untwining Anti-Tumor and Immunosuppressive Effects of JAK Inhibitors—A Strategy for Hematological Malignancies? Klara Klein 1, Dagmar Stoiber 2, Veronika Sexl 1 and Agnieszka Witalisz-Siepracka 1,2,* 1 Department of Biomedical Science, Institute of Pharmacology and Toxicology, University of Veterinary Medicine Vienna, 1210 Vienna, Austria; [email protected] (K.K.); [email protected] (V.S.) 2 Department of Pharmacology, Physiology and Microbiology, Division Pharmacology, Karl Landsteiner University of Health Sciences, 3500 Krems, Austria; [email protected] * Correspondence: [email protected] or [email protected] Simple Summary: The Janus kinase-signal transducer and activator of transcription (JAK-STAT) pathway is aberrantly activated in many malignancies. Inhibition of this pathway via JAK inhibitors (JAKinibs) is therefore an attractive therapeutic strategy underlined by Ruxolitinib (JAK1/2 inhibitor) being approved for the treatment of myeloproliferative neoplasms. As a consequence of the crucial role of the JAK-STAT pathway in the regulation of immune responses, inhibition of JAKs suppresses the immune system. This review article provides a thorough overview of the current knowledge on JAKinibs’ effects on immune cells in the context of hematological malignancies. We also discuss the potential use of JAKinibs for the treatment of diseases in which lymphocytes are the source of the malignancy. Citation: Klein, K.; Stoiber, D.; Sexl, Abstract: The Janus kinase-signal transducer and activator of transcription (JAK-STAT) pathway V.; Witalisz-Siepracka, A. Untwining propagates signals from a variety of cytokines, contributing to cellular responses in health and disease. Anti-Tumor and Immunosuppressive Gain of function mutations in JAKs or STATs are associated with malignancies, with JAK2V617F being Effects of JAK Inhibitors—A Strategy the main driver mutation in myeloproliferative neoplasms (MPN). -
Activin Signaling Informs the Graded Pattern of Terminal Mitosis and Hair Cell
bioRxiv preprint doi: https://doi.org/10.1101/380055; this version posted July 30, 2018. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. 1 CLASSIFICATION: Developmental Biology, Neuroscience 2 3 TITLE: Activin signaling informs the graded pattern of terminal mitosis and hair cell 4 differentiation in the mammalian cochlea 5 6 SHORT TITLE: Activin signaling instructs auditory hair cell differentiation 7 8 9 AUTHOR AFFILIATIONS: 10 Meenakshi Prajapati-DiNubila1, 2* Ana Benito-Gonzalez1, 2*, Erin J. Golden1, 2#, Shuran Zhang1,2 11 and Angelika Doetzlhofer1, 2 12 1. Solomon H. Snyder Department of Neuroscience1 and Center for Sensory Biology2, 13 Johns Hopkins University, School of Medicine Baltimore, MD 21205, USA 14 * Equal contribution 15 #Current address: Department of Cell and Developmental Biology and the Rocky Mountain 16 Taste and Smell Center University of Colorado, Anschutz Medical Campus, Aurora, CO 80045, 17 USA. 18 19 CORRESPONDENCE ADDRESSED TO: Angelika Doetzlhofer, Ph.D. 20 855 North Wolfe Street, Rangos 433, Baltimore, MD 21205, USA ([email protected]) 21 22 23 Keywords: Inner ear, cochlea, differentiation, hair cell, Activin signaling, follistatin. 24 25 1 bioRxiv preprint doi: https://doi.org/10.1101/380055; this version posted July 30, 2018. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. 26 ABSTRACT 27 The mammalian auditory sensory epithelium has one of the most stereotyped cellular 28 patterns known in vertebrates. Mechano-sensory hair cells are arranged in precise rows, with 29 one row of inner and three rows of outer hair cells spanning the length of the spiral-shaped 30 sensory epithelium. -
The TGF-Β Family in the Reproductive Tract
Downloaded from http://cshperspectives.cshlp.org/ on September 25, 2021 - Published by Cold Spring Harbor Laboratory Press The TGF-b Family in the Reproductive Tract Diana Monsivais,1,2 Martin M. Matzuk,1,2,3,4,5 and Stephanie A. Pangas1,2,3 1Department of Pathology and Immunology, Baylor College of Medicine, Houston, Texas 77030 2Center for Drug Discovery, Baylor College of Medicine, Houston, Texas 77030 3Department of Molecular and Cellular Biology, Baylor College of Medicine Houston, Texas 77030 4Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, Texas 77030 5Department of Pharmacology, Baylor College of Medicine, Houston, Texas 77030 Correspondence: [email protected]; [email protected] The transforming growth factor b (TGF-b) family has a profound impact on the reproductive function of various organisms. In this review, we discuss how highly conserved members of the TGF-b family influence the reproductive function across several species. We briefly discuss how TGF-b-related proteins balance germ-cell proliferation and differentiation as well as dauer entry and exit in Caenorhabditis elegans. In Drosophila melanogaster, TGF-b- related proteins maintain germ stem-cell identity and eggshell patterning. We then provide an in-depth analysis of landmark studies performed using transgenic mouse models and discuss how these data have uncovered basic developmental aspects of male and female reproductive development. In particular, we discuss the roles of the various TGF-b family ligands and receptors in primordial germ-cell development, sexual differentiation, and gonadal cell development. We also discuss how mutant mouse studies showed the contri- bution of TGF-b family signaling to embryonic and postnatal testis and ovarian development. -
Src Directly Tyrosine-Phosphorylates STAT5 on Its Activation Site and Is Involved in Erythropoietin-Induced Signaling Pathway
Oncogene (2001) 20, 6643 ± 6650 ã 2001 Nature Publishing Group All rights reserved 0950 ± 9232/01 $15.00 www.nature.com/onc Src directly tyrosine-phosphorylates STAT5 on its activation site and is involved in erythropoietin-induced signaling pathway Yuichi Okutani1, Akira Kitanaka1, Terukazu Tanaka*,2, Hiroshi Kamano6, Hiroaki Ohnishi3, Yoshitsugu Kubota4, Toshihiko Ishida1 and Jiro Takahara5 1First Department of Internal Medicine, Kagawa Medical University, Kagawa 761-0793, Japan; 2Environmental Health Sciences, Kagawa Medical University, Kagawa 761-0793, Japan; 3Laboratory Medicine, Kagawa Medical University, Kagawa 761-0793, Japan; 4Transfusion Medicine, Kagawa Medical University, Kagawa 761-0793, Japan; 5Kagawa Medical University, Kagawa 761- 0793, Japan; 6Health Science Center, Kagawa University, Kagawa 760-8521, Japan Signal transducers and activators of transcription Growth and dierentiation of hematopoietic cells are (STAT) proteins are transcription factors activated by regulated by the interaction of cell surface receptors phosphorylation on tyrosine residues after cytokine with their speci®c cytokines or growth factors. While stimulation. In erythropoietin receptor (EPOR)-mediated some of these receptors transmit signals via their signaling, STAT5 is tyrosine-phosphorylated by EPO intrinsic protein tyrosine kinase (PTK) activity, others stimulation. Although Janus Kinase 2 (JAK2) is reported use cytoplasmic non-receptor PTK for mediating to play a crucial role in EPO-induced activation of signals (van der Geer et al., 1994). The binding of STAT5, it is unclear whether JAK2 alone can tyrosine- erythropoietin (EPO) to an erythropoietin receptor phosphorylate STAT5 after EPO stimulation. Several (EPOR) which does not contain any intrinsic PTK studies indicate that STAT activation is caused by activity induces rapid and transient tyrosine phosphor- members of other families of protein tyrosine kinases ylation of intracellular proteins (Constantinescu et al., such as the Src family. -
Interpretation of Cytokine Signaling Through the Transcription Factors STAT5A and STAT5B
Downloaded from genesdev.cshlp.org on September 25, 2021 - Published by Cold Spring Harbor Laboratory Press REVIEW Interpretation of cytokine signaling through the transcription factors STAT5A and STAT5B Lothar Hennighausen1 and Gertraud W. Robinson Laboratory of Genetics and Physiology, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA Transcription factors from the family of Signal Trans- the “wrong” STATs and thus acquire inappropriate cues. ducers and Activators of Transcription (STAT) are acti- We propose that mice with mutations in various com- vated by numerous cytokines. Two members of this fam- ponents of the JAK–STAT signaling pathway are living ily, STAT5A and STAT5B (collectively called STAT5), laboratories, which will provide insight into the versa- have gained prominence in that they are activated by a tility of signaling hardware and the adaptability of the wide variety of cytokines such as interleukins, erythro- software. poietin, growth hormone, and prolactin. Furthermore, constitutive STAT5 activation is observed in the major- ity of leukemias and many solid tumors. Inactivation Historical perspective studies in mice as well as human mutations have pro- In 1994, Bernd Groner and colleagues (Wakao et al. vided insight into many of STAT5’s functions. Disrup- 1994), then at the Friedrich Miescher Institute in Basel, tion of cytokine signaling through STAT5 results in a cloned a cDNA from lactating ovine mammary tissue variety of cell-specific effects, ranging from a defective that encoded a transcription factor promoting prolactin- immune system and impaired erythropoiesis, the com- induced transcription of milk protein genes in mammary plete absence of mammary development during preg- epithelium. -
Matrisome-Associated Gene Expression Patterns Correlating with TIMP2 in Cancer David Peeney1*, Yu Fan2, Trinh Nguyen 2, Daoud Meerzaman2 & William G
www.nature.com/scientificreports OPEN Matrisome-Associated Gene Expression Patterns Correlating with TIMP2 in Cancer David Peeney1*, Yu Fan2, Trinh Nguyen 2, Daoud Meerzaman2 & William G. Stetler-Stevenson 1 Remodeling of the extracellular matrix (ECM) to facilitate invasion and metastasis is a universal hallmark of cancer progression. However, a defnitive therapeutic target remains to be identifed in this tissue compartment. As major modulators of ECM structure and function, matrix metalloproteinases (MMPs) are highly expressed in cancer and have been shown to support tumor progression. MMP enzymatic activity is inhibited by the tissue inhibitor of metalloproteinase (TIMP1–4) family of proteins, suggesting that TIMPs may possess anti-tumor activity. TIMP2 is a promiscuous MMP inhibitor that is ubiquitously expressed in normal tissues. In this study, we address inconsistencies in the literature regarding the role of TIMP2 in tumor progression by analyzing co-expressed genes in tumor vs. normal tissue. Utilizing data from The Cancer Genome Atlas and Genotype-Tissue expression studies, focusing on breast and lung carcinomas, we analyzed the correlation between TIMP2 expression and the transcriptome to identify a list of genes whose expression is highly correlated with TIMP2 in tumor tissues. Bioinformatic analysis of the identifed gene list highlights a core of matrix and matrix- associated genes that are of interest as potential modulators of TIMP2 function, thus ECM structure, identifying potential tumor microenvironment biomarkers and/or therapeutic targets for further study. Matrix metalloproteinases (MMPs) are a family of zinc-dependent endopeptidases that are the major mediators of extracellular matrix (ECM) breakdown and turnover. Humans express 23 MMPs and these play a critical role in tissue development, homeostasis and disease progression. -
Induced Heterotopic Ossification in Mice Expre
Maekawa et al. Orphanet Journal of Rare Diseases (2020) 15:122 https://doi.org/10.1186/s13023-020-01406-8 RESEARCH Open Access Prophylactic treatment of rapamycin ameliorates naturally developing and episode -induced heterotopic ossification in mice expressing human mutant ACVR1 Hirotsugu Maekawa1,2, Shunsuke Kawai1,2,3, Megumi Nishio3, Sanae Nagata1, Yonghui Jin3,4, Hiroyuki Yoshitomi2,3, Shuichi Matsuda2 and Junya Toguchida1,2,3,4* Abstract Background: Fibrodysplasia ossificans progressiva (FOP) is a rare autosomal-dominant disease characterized by heterotopic ossification (HO) in soft tissues and caused by a mutation of the ACVR1A/ALK2 gene. Activin-A is a key molecule for initiating the process of HO via the activation of mTOR, while rapamycin, an mTOR inhibitor, effectively inhibits the Activin-A-induced HO. However, few reports have verified the effect of rapamycin on FOP in clinical perspectives. Methods: We investigated the effect of rapamycin for different clinical situations by using mice conditionally expressing human mutant ACVR1A/ALK2 gene. We also compared the effect of rapamycin between early and episode-initiated treatments for each situation. Results: Continuous, episode-independent administration of rapamycin reduced the incidence and severity of HO in the natural course of FOP mice. Pinch-injury induced HO not only at the injured sites, but also in the contralateral limbs and provoked a prolonged production of Activin-A in inflammatory cells. Although both early and injury-initiated treatment of rapamycin suppressed HO in the injured sites, the former was more effective at preventing HO in the contralateral limbs. Rapamycin was also effective at reducing the volume of recurrent HO after the surgical resection of injury-induced HO, for which the early treatment was more effective. -
Cumulin and FSH Cooperate to Regulate Inhibin B and Activin B Production by Human Granulosa-Lutein Cells in Vitro Dulama Richani
1 Cumulin and FSH cooperate to regulate inhibin B and activin B production by human 2 granulosa-lutein cells in vitro 3 4 Dulama Richani*1, Katherine Constance1, Shelly Lien1, David Agapiou1, William A. 5 Stocker2,3, Mark P. Hedger4, William L. Ledger1, Jeremy G. Thompson5, David M. 6 Robertson1, David G. Mottershead5,6, Kelly L. Walton2, Craig A. Harrison2 and Robert B. 7 Gilchrist1 8 9 1 Fertility and Research Centre, School of Women’s and Children’s Health, University of 10 New South Wales Sydney, Australia 11 2 Department of Physiology, Monash Biomedicine Discovery Institute, Monash University, 12 Clayton, Australia 13 3 Department of Chemistry and Biotechnology, Swinburne University of Technology, 14 Hawthorn, Victoria 3122, Australia 15 4 Centre for Reproductive Health, Hudson Institute of Medical Research, Clayton, VIC, 16 Australia 17 5 Robinson Research Institute, Adelaide Medical School, The University of Adelaide, 18 Australia 19 6 Institute for Science and Technology in Medicine, School of Pharmacy, Keele University, 20 Newcastle-under-Lyme, UK 21 22 Short Title: Cumulin and FSH jointly regulate inhibin/activin B 23 24 Corresponding author: 25 *Dulama Richani ([email protected]) 1 26 Wallace Wurth Building, UNSW Sydney, Kensington, NSW 2052, Australia 27 28 Re-print requests: 29 Dulama Richani ([email protected]) 30 Wallace Wurth Building, UNSW Sydney, Kensington, NSW 2052, Australia 31 32 Key words: 33 GDF9, BMP15, cumulin, FSH, inhibin, activin 34 35 Funding: 36 The work was funded by National Health and Medical Research Council of Australia grants 37 (APP1017484, APP1024358, APP1121504 awarded to DGM, CAH, and RBG, respectively) 38 and fellowships (APP1023210, APP1117538 awarded to RBG), and by Strategic Funds from 39 the University of New South Wales Sydney awarded to RBG. -
Cancer Letters 356 (2015) 819–827
Cancer Letters 356 (2015) 819–827 Contents lists available at ScienceDirect Cancer Letters journal homepage: www.elsevier.com/locate/canlet Original Articles Activin signal promotes cancer progression and is involved in cachexia in a subset of pancreatic cancer Yosuke Togashi a, Akihiro Kogita a,b, Hiroki Sakamoto c, Hidetoshi Hayashi a, Masato Terashima a, Marco A. de Velasco a, Kazuko Sakai a, Yoshihiko Fujita a, Shuta Tomida a, Masayuki Kitano c, Kiyotaka Okuno b, Masatoshi Kudo c, Kazuto Nishio a,* a Department of Genome Biology, Kindai University Faculty of Medicine, Osaka, Japan b Department of Surgery, Kindai University Faculty of Medicine, Osaka, Japan c Department of Gastroenterology and Hepatology, Kindai University Faculty of Medicine, Osaka, Japan ARTICLE INFO ABSTRACT Article history: We previously reported that activin produces a signal with a tumor suppressive role in pancreatic cancer Received 12 August 2014 (PC). Here, the association between plasma activin A and survival in patients with advanced PC was in- Received in revised form 29 October 2014 vestigated. Contrary to our expectations, however, patients with high plasma activin A levels had a Accepted 29 October 2014 significantly shorter survival period than those with low levels (median survival, 314 days vs. 482 days, P = 0.034). The cellular growth of the MIA PaCa-2 cell line was greatly enhanced by activin A via non- Keywords: SMAD pathways. The cellular growth and colony formation of an INHBA (beta subunit of inhibin)- Activin signal overexpressed cell line were also enhanced. In a xenograft study, INHBA-overexpressed cells tended to INHBA INHBB result in a larger tumor volume, compared with a control.